PolyPid

PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PolyPid advances SHIELD II trial, secures financing for growth

PolyPid's Q2 2024 earnings call showcased progress in the SHIELD II trial and financial resilience through secured financing.
Strong leadership appointments and positive feedback on D-PLEX100's potential highlight the company's strategic strengths.
While facing timeline risks and financial challenges, PolyPid remains focused on advancing D-PLEX100 and seizing growth opportunities.
Overall, PolyPid's performance reflects a balanced approach to innovation, financial management, and commitment to achieving key milestones.

PolyPid advances SHIELD II trial with positive outlook amid financial challenges

PolyPid's Q3 2024 earnings call highlighted progress in SHIELD II trial, financial position, and challenges with increased R&D expenses. The company's focus on advancing clinical trials and managing expenses while exploring growth opportunities is key for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.

PolyPid Ltd. (NASDAQ:PYPD ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Executive Officer Ori Warshavsky - Chief Operating Officer, U.S. Jonny Missulawin - Chief Financial Officer Conference Call Participants Roy Buchanan - JMP Chase Knickerbocker - Craig-Hallum Operator Greetings, and welcome to the PolyPid Third Quarter 2024 Conference Call.

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

PETACH TIKVA, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will participate in investor meetings at the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, in New York, NY.

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

PETACH TIKVA, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 13, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

SHIELD I Study is One of the Largest Phase 3 Trials in the Prevention of SSIs in Colorectal Resection Conducted in Over a Decade

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Unblinded Interim Analysis to be Conducted During the Current Quarter Top-line Results Anticipated in First Quarter of 2025 PETACH TIKVA, Israel, Oct. 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled the last patient required in order to conduct the planned unblinded interim analysis in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PETACH TIKVA, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will participate in the following three investor conferences:

PolyPid to Participate in Three Upcoming Fall Investor Conferences

PolyPid Ltd (NASDAQ:PYPD ) Q2 2024 Results Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Executive Officer Ori Warshavsky - Chief Operating Officer, US Jonny Missulawin - Chief Financial Officer Conference Call Participants Roy Buchanan - JMP Securities Raghuram Selvaraju - H.C. Wainwright & Co. Operator Greetings and welcome to the PolyPid Second Quarter 2024 Conference Call.

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

Funding Extends Company's Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

PETACH TIKVA, Israel, July 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

PETACH TIKVA, Israel, June 10, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, June 17, 2024, at 10:00 AM ET, to discuss the significant unmet medical need in surgical site infections and provide an update on the Company's ongoing D-PLEX100 Phase 3 trial. To register, click here .

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

PolyPid Ltd (NASDAQ:PYPD ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Brian Ritchie - IR Dikla Czaczkes Akselbrad - CEO & Director Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer, US Conference Call Participants Roy Buchanan - JMP Operator Thank you all for participating in PolyPid's First Quarter 2024 Earnings Conference Call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid's Chief Financial Officer and Ori Warshavsky, Chief Operating Officer, US of PolyPid.

PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript

More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100  for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that company management will present at the Citizens JMP Life Sciences Conference taking place in New York, NY, from May 13 – 14, 2024.

PolyPid to Participate in Citizens JMP Life Sciences Conference

Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results Expected in Second Half of 2024 PETACH TIKVA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled the 200th patient in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024.

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

PolyPid Ltd. (PYPD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100  for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Recent Successful $16 Million Financing Extends Company's Cash Runway Through Late Q3 2024 and Beyond Expected Timing of Unblinded Interim Analysis; Potential Additional $19 Million if Warrants are Exercised to Fund PolyPid to the Start of a Planned New Drug Application Submission for D-PLEX100  PETACH TIKVA, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled and randomized the 100th patient in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

PETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities purchase agreement for a private placement financing (the “PIPE”) for $16.2 million in gross proceeds priced at the 5-day volume weighted average price as of January 2, 2024 of $4.81 per share.

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

PolyPid Ltd. (NASDAQ:PYPD ) Q3 2023 Earnings Conference Call November 11, 2023 8:00 AM ET Company Participants Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer Conference Call Participants Roy Buchanan - JMP Raghuram Selvaraju - H.C.

PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript

Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX 100  for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal

News for PolyPid Stock (PYPD)